Latest RVTY news

Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?

Zacks Investment Research · Wed, 16 Sep 2026 06:16:00 -0400

Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript

Seeking Alpha · Tue, 15 Sep 2026 11:51:37 -0400

Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript

Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · Mon, 14 Sep 2026 11:31:37 -0400

Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Revvity to Acquire Human Cell Design to Boost Metabolic Discovery

Zacks Investment Research · Fri, 11 Sep 2026 12:20:49 -0400

RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.

Why Revvity (RVTY) is a Top Momentum Stock for the Long-Term

Zacks Investment Research · Thu, 10 Sep 2026 10:50:54 -0400

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Seeking Alpha · Wed, 09 Sep 2026 12:57:06 -0400

Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Business Wire · Wed, 09 Sep 2026 06:00:00 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including.

Market information is provided for research and visualization and is not investment advice.